Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the exact moment Amphastar Pharmaceuticals discloses an FDA manufacturing observation or a change in its insulin API strategy can feel like hunting for a needle in a 300-page haystack. Because every cGMP deviation, pipeline update, and recall risk must be reported, AMPH鈥檚 SEC documents are dense with technical language that even seasoned analysts find daunting.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries that translate each filing into plain English. Want the highlights of an Amphastar Pharmaceuticals annual report 10-K simplified? Our platform extracts segment revenues, R&D spend, and key FDA milestones in seconds. Need the latest Amphastar Pharmaceuticals quarterly earnings report 10-Q filing? It arrives with instant ratios and trend graphs. Form 8-K material events鈥攕uch as trial results or supply-chain contracts鈥攁re pushed to you with Amphastar Pharmaceuticals 8-K material events explained so you never miss a market-moving update.
For governance insights, track Amphastar Pharmaceuticals insider trading Form 4 transactions the moment executives file; our alerts surface patterns in Amphastar Pharmaceuticals executive stock transactions Form 4. Dig into the proxy for Amphastar Pharmaceuticals proxy statement executive compensation or explore Amphastar Pharmaceuticals earnings report filing analysis to compare margin shifts. Whether you鈥檙e understanding Amphastar Pharmaceuticals SEC documents with AI for compliance checks or evaluating competitive position, Stock Titan鈥檚 coverage of every 10-K, 10-Q, 8-K, S-1, and real-time Amphastar Pharmaceuticals Form 4 insider transactions gives you the clarity and speed required to make informed decisions.
Amphastar Pharmaceuticals entered a license agreement with Nanjing Anji Biotechnology granting Amphastar exclusive rights in the United States and Canada to develop, make, use and commercialize products incorporating certain compounds, including three identified Licensed Products. Amphastar paid an $0.75 million earnest payment and a $5.25 million upfront fee on signing and agreed to up to $42 million in development milestones and up to $225 million in sales milestones, plus royalty payments capped at $22.5 million per product per year and a $60 million accumulated cap per product. Amphastar will share a percentage of sublicense income with Anji, and Anji will pay Amphastar royalties on net sales tied to Amphastar-licensed patents outside the Territory.
The agreement term runs product-by-product and region-by-region to the tenth anniversary of first commercial sale with an Amphastar option to extend up to ten additional years or until patent claims lapse. The company disclosed customary forward-looking statements and identified risks including regulatory approval, commercialization success, legal and regulatory changes, and supply-chain disruptions, and incorporated the full Agreement by reference to be filed as an exhibit.
Amphastar Pharmaceuticals (AMPH) 鈥� SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar鈥檚 total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.
Form 4 Overview 鈥� Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen鈥檚 direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director鈥檚 reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.
FAQ
What is the current stock price of Amphastar Pharma (AMPH)?
What is the market cap of Amphastar Pharma (AMPH)?
